Common Side Effects of Opdivo
Opdivo (nivolumab), a PD-1 inhibitor used for cancers like melanoma and lung cancer, often causes fatigue, musculoskeletal pain, rash, itching, cough, decreased appetite, constipation, diarrhea, nausea, and dyspnea. These occur in more than 20% of patients in clinical trials.[1]
Serious Immune-Related Side Effects
Opdivo can trigger immune-mediated reactions by overactivating the immune system, affecting organs like the lungs, intestines, liver, endocrine glands, skin, kidneys, and nerves. Key risks include:
- Pneumonitis: Lung inflammation (3-5% incidence, potentially fatal).
- Colitis: Severe diarrhea or bowel perforation (1-5%).
- Hepatitis: Liver enzyme elevation or failure (1-5%).
- Endocrinopathies: Thyroid issues, adrenal insufficiency, or type 1 diabetes (5-10%).
- Skin reactions: Severe rash or Stevens-Johnson syndrome (rare but serious).
- Neuropathies or encephalitis: Nerve or brain inflammation (less than 1%, can be life-threatening).[1][2]
These require immediate medical intervention, often with steroids or immunosuppressants.
Side Effects by Combination Therapy
When combined with ipilimumab (Yervoy), risks intensify:
- Severe immune reactions rise to 40-60%, including higher rates of colitis (up to 20%) and pneumonitis (up to 10%).
- Chemotherapy combos increase nausea, anemia, and neutropenia.[1]
Side Effects in Specific Cancers or Populations
- Melanoma: Higher skin and endocrine issues.
- Lung cancer: More respiratory events.
- Pediatric or elderly patients face amplified fatigue and infection risks; data is limited for under-12s.[1][2]
What Happens If Side Effects Occur?
Mild effects may resolve with dose adjustments; severe ones lead to permanent discontinuation in 20-30% of cases. Monitor with regular labs and imaging. Fatal outcomes occur in under 1%, often from immune reactions.[1]
Long-Term Risks and Patient Concerns
Late-onset effects like hypothyroidism or hypophysitis persist post-treatment. Fertility impacts are unclear; avoid pregnancy due to fetal harm risk. Patients report ongoing fatigue affecting quality of life.[2]
[1]: https://www.opdivo.com/safety
[2]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s400lbl.pdf